Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2020. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 1470397. A live webcast of the presentation will be available on the Investors
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2020.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 1470397. A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Investors
Mark
Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
